MA71734A - Composés pour le traitement du cancer - Google Patents
Composés pour le traitement du cancerInfo
- Publication number
- MA71734A MA71734A MA71734A MA71734A MA71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A MA 71734 A MA71734 A MA 71734A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263406081P | 2022-09-13 | 2022-09-13 | |
| US202263419451P | 2022-10-26 | 2022-10-26 | |
| US202263435170P | 2022-12-23 | 2022-12-23 | |
| US202363536249P | 2023-09-01 | 2023-09-01 | |
| EP23783180.5A EP4568948A1 (fr) | 2022-09-13 | 2023-09-11 | Composés pour le traitement du cancer |
| PCT/US2023/032420 WO2024059010A1 (fr) | 2022-09-13 | 2023-09-11 | Composés pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71734A true MA71734A (fr) | 2025-05-30 |
Family
ID=88237760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71734A MA71734A (fr) | 2022-09-13 | 2023-09-11 | Composés pour le traitement du cancer |
| MA71293A MA71293A1 (fr) | 2022-09-13 | 2023-09-11 | Composés pour le traitement du cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71293A MA71293A1 (fr) | 2022-09-13 | 2023-09-11 | Composés pour le traitement du cancer |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP4568948A1 (fr) |
| JP (1) | JP2025530333A (fr) |
| KR (1) | KR20250067170A (fr) |
| CN (1) | CN120112518A (fr) |
| AU (1) | AU2023342774A1 (fr) |
| CA (1) | CA3264256A1 (fr) |
| CL (1) | CL2025000672A1 (fr) |
| CO (1) | CO2025003099A2 (fr) |
| CR (1) | CR20250124A (fr) |
| DO (1) | DOP2025000057A (fr) |
| GE (1) | GEAP202516737A (fr) |
| IL (1) | IL319513A (fr) |
| JO (1) | JOP20250057A1 (fr) |
| MA (2) | MA71734A (fr) |
| MX (1) | MX2025002817A (fr) |
| PE (1) | PE20251692A1 (fr) |
| TW (1) | TW202426427A (fr) |
| WO (1) | WO2024059010A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202854A1 (fr) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Inhibiteurs de cdk4 et combinaisons avec des inhibiteurs de cdk2 ou d'autres agents destinés à être utilisés dans le traitement du cancer |
| WO2025240536A1 (fr) * | 2024-05-15 | 2025-11-20 | Nikang Therapeutics, Inc. | Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante d'une cycline et/ou la kinase 4 dépendante d'une cycline par l'intermédiaire de la voie ubiquitine-protéasome |
| WO2026024674A1 (fr) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Méthodes de traitement de cancers associés à skp2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159120A0 (en) * | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| BR112022015110A2 (pt) | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| TW202227430A (zh) | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2022135365A1 (fr) * | 2020-12-22 | 2022-06-30 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Inhibiteurs de kinase de cyclopentane disubstitués |
| MX2023009086A (es) | 2021-02-12 | 2023-08-08 | Relay Therapeutics Inc | Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos. |
-
2023
- 2023-09-11 GE GEAP202516737A patent/GEAP202516737A/en unknown
- 2023-09-11 CR CR20250124A patent/CR20250124A/es unknown
- 2023-09-11 PE PE2025000541A patent/PE20251692A1/es unknown
- 2023-09-11 CN CN202380074814.7A patent/CN120112518A/zh active Pending
- 2023-09-11 KR KR1020257011828A patent/KR20250067170A/ko active Pending
- 2023-09-11 MA MA71734A patent/MA71734A/fr unknown
- 2023-09-11 CA CA3264256A patent/CA3264256A1/fr active Pending
- 2023-09-11 AU AU2023342774A patent/AU2023342774A1/en active Pending
- 2023-09-11 JP JP2025515376A patent/JP2025530333A/ja active Pending
- 2023-09-11 WO PCT/US2023/032420 patent/WO2024059010A1/fr not_active Ceased
- 2023-09-11 EP EP23783180.5A patent/EP4568948A1/fr active Pending
- 2023-09-11 MA MA71293A patent/MA71293A1/fr unknown
- 2023-09-11 IL IL319513A patent/IL319513A/en unknown
- 2023-09-12 TW TW112134698A patent/TW202426427A/zh unknown
-
2025
- 2025-03-10 DO DO2025000057A patent/DOP2025000057A/es unknown
- 2025-03-10 MX MX2025002817A patent/MX2025002817A/es unknown
- 2025-03-11 CL CL2025000672A patent/CL2025000672A1/es unknown
- 2025-03-11 CO CONC2025/0003099A patent/CO2025003099A2/es unknown
- 2025-03-12 JO JOJO/P/2025/0057A patent/JOP20250057A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202516737A (en) | 2025-06-10 |
| TW202426427A (zh) | 2024-07-01 |
| JOP20250057A1 (ar) | 2025-03-12 |
| CL2025000672A1 (es) | 2025-07-11 |
| CR20250124A (es) | 2025-05-07 |
| KR20250067170A (ko) | 2025-05-14 |
| WO2024059010A1 (fr) | 2024-03-21 |
| JP2025530333A (ja) | 2025-09-11 |
| DOP2025000057A (es) | 2025-04-08 |
| CN120112518A (zh) | 2025-06-06 |
| MA71293A1 (fr) | 2026-06-30 |
| MX2025002817A (es) | 2025-04-02 |
| CO2025003099A2 (es) | 2025-03-27 |
| CA3264256A1 (fr) | 2024-03-21 |
| AU2023342774A1 (en) | 2025-02-27 |
| PE20251692A1 (es) | 2025-07-02 |
| EP4568948A1 (fr) | 2025-06-18 |
| IL319513A (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| MA71551A (fr) | Composés macrocycles pour le traitement du cancer | |
| MA71370A (fr) | Inhibiteurs macrocycliques de kras pour le traitement du cancer | |
| MA71325A (fr) | Inhibiteur de kras g12c pour le traitement du cancer | |
| EP3935050A4 (fr) | Composés hétérocycliques pour traitement médical | |
| EP4467154A4 (fr) | Médicament pour le traitement ou la prévention du cancer | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| EP4229048A4 (fr) | Acylsulfonamides substitués pour le traitement du cancer | |
| EP3986863A4 (fr) | Inhibiteurs de glycolate oxydase pour le traitement d'une maladie | |
| EP4259147A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3478284A4 (fr) | Composés et compositions pour le traitement du cancer | |
| EP3990458A4 (fr) | Composés pour le traitement du cancer | |
| EP3877382A4 (fr) | Nouveaux composés pour le traitement de maladies respiratoires | |
| EP4288059A4 (fr) | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP4263584A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP4251143A4 (fr) | Composition de benzènesulfonamide pour le traitement du mélanome | |
| EP3793548A4 (fr) | Composés pour le traitement du cancer du pancréas | |
| EP4294448A4 (fr) | Polythérapie génique pour le traitement du cancer métastatique | |
| EP4121403A4 (fr) | Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus | |
| EP4146203A4 (fr) | Inhibiteur de dhodh pour le traitement de la covid-19 | |
| EP4174087A4 (fr) | Médicament pour le traitement de tumeur | |
| MA56186A (fr) | Composés pour le traitement d'une maladie respiratoire | |
| EP4110923A4 (fr) | Méthodes et compositions pour le traitement du cancer déficient en apc |